



AVICANNA™

Q1 2026

An International Biopharmaceutical Strategy

TSX: AVCN

OTCQX: AVCNF

FSE: ONN

avicanna.com



DISCLAIMER & NOTICE REGARDING FORWARD LOOKING STATEMENTS

Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities legislation and regulations or other applicable securities laws (“forward-looking statements”). Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, milestones, expectations or intentions regarding the future including words or phrases such as “anticipate,” “objective,” “may,” “will,” “might,” “should,” “could,” “can,” “intend,” “expect,” “believe,” “estimate,” “predict,” “potential,” “plan,” “is designed to” or similar expressions suggest future outcomes or the negative thereof or similar variations. Forward-looking statements may include, among other things, statements and information about anticipated dates for revenue recognition; business strategy, product development, timing of product development, events and courses of action, anticipated dates for product launches; our plans for future products and enhancements of existing products; designs for future product packaging; expected completion dates for clinical studies/trials and product development; expected results of clinical trials; the granting of any certifications, licenses, or registrations; our future growth strategy; our future intellectual property, research and development, product formulations and business lines; each of our expected upcoming milestones; and our anticipated trends and challenges in the markets in which we operate. Such forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates, and beliefs at the they are made. Forward-looking statements are based on numerous assumptions regarding present and future business strategies and the environment in which Avicanna may operate in the future, including the demand for our products, anticipated costs and ability to achieve goals, expected outcomes for clinical trials, the timely completion of research and development initiatives and the price of cannabis and cannabis related products.

Although we believe the assumptions underlying these forward-looking statements are reasonable, they may prove to be incorrect. Given these risks, uncertainties and assumptions, you should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance, or achievements. Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to, business, economic and capital market conditions; the ability to manage operating expenses, which may adversely impact financial condition; ability to remain competitive as other better financed competitors develop and release competitive products; regulatory uncertainties; weather patterns; market conditions and the demand and pricing for products; demand and pricing of cannabis and cannabidiol; security threats, including loss/theft of proprietary technology; relationships with regulatory bodies, our customers, distributors and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers’ needs; ability to attract, retain and motivate qualified personnel; competition in our industry; ability to maintain technological leadership; impact of technology changes on our products and industry; failure to develop new and innovative products; ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; impact of intellectual property litigation that could materially and adversely affect our business; ability to manage working capital; dependence on key personnel; and additional risk factors included elsewhere in Avicanna’s public disclosures, including, without limitation, under the heading “Risk Factors” in its annual information form dated April 11, 2025 and final short form prospectus dated November 27, 2020, in each case filed with the Canadian securities regulators and available under Avicanna’s profile on SEDAR+ at www.sedarplus.ca.

Although Avicanna has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. Avicanna is an early-stage company with a short operating history; and it may not actually achieve its plans, projections, or expectations. Important factors that could cause actual results to differ materially from Avicanna’s expectations include, consumer sentiment towards Avicanna’s products and cannabis and cannabis related technology generally, litigation, global economic climate, equipment failures, increase in operating costs, decrease in the price of cannabis and cannabidiol, security threats including a loss or theft of intellectual property, adverse medical findings, government regulations, loss of key employees and consultants, additional funding requirements, changes in laws, technology failures, competition, failure of counterparties to perform their contractual obligations, delays or unexpected expenditures in completion of clinical trials, or unexpected delays in the commercialization of products. Forward-looking statements contained in this presentation are as of the date of this presentation and, except as required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of our representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this presentation. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the information in this presentation. Avicanna disclaims any intention or obligation to update or revise any forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, unless required pursuant to applicable securities law. Readers are cautioned that the forward-looking statements contained in this document should not be used for purposes other than for which it is disclosed herein. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

All financial information included in this document is unaudited. There is a material risk that the audited financial results will differ significantly from the unaudited financial information presented herein. Certain information in this presentation is based on management estimates. Such estimates have been made in good faith and represent the current beliefs of management. Management believes that such estimates are founded on reasonable grounds. However, by their nature, estimates may not be correct or complete. Accordingly, no representation or warranty (express or implied) is given that such estimates are accurate, up-to-date, correct or complete. Certain information contained herein is based on, or derived from, information provided by independent third-party sources. Avicanna believes that such information is accurate and that the sources from which it has been obtained are reliable. Where this presentation quotes any information or data from any third-party source, it should not be interpreted that Avicanna has adopted or endorsed such information or data as being accurate. Avicanna has not independently verified any of such information from third-party sources or any underlying assumptions. Accordingly, Avicanna makes no representation or warranty (express or implied) on the fairness, accuracy, completeness or correctness of any such third-party information.

No securities commission or similar authority of Canada, the United States or any other jurisdiction has reviewed or in any way passed upon this presentation, and any representation to the contrary is an offence. Readers should not construe the contents of this presentation as investment, legal, tax, regulatory, financial or accounting advice and are urged to consult with their own advisers in relation to such matters.





Corporate Overview

An International Medical and Biopharmaceutical Strategy

Established Commercial Platform

- 4 commercial stage business pillars
- 50+ commercialized proprietary SKUs
- Addressing a global medical and pharmaceutical opportunity
- Completed transactions in 20+ countries

Industry Leading Scientific Platform

- Robust intellectual property portfolio
- Partnerships with leading academic and clinical institutions
- Indication specific pharmaceutical pipeline
- JLABS @ Johnson and Johnson incubated – at MaRS

Business Pillars



1.1

Medical Cannabis Products



1.2

Medical Cannabis Care Platform*



1.3

Pharmaceutical Pipeline



1.4

Active Pharmaceutical Ingredients

*MyMedi.ca is operated by Northern Green Canada for the Canadian market

1.1 Rho Phyto

Advanced Medical Cannabis Formulary



Comprehensive formulary of cannabinoid-based medicine with a range of doses and delivery systems.



Evidence based and proprietary drug delivery systems.



Supported by pre-clinical and clinical data as well as real world evidence.

THC

CBD

CBG

CBN



1.1.1 The Canadian Commercial Platform

| National Medical Channels | Provincial Retail Channels |
|---|---|
|  |  |

50
Proprietary commercial SKUs

8
National medical cannabis portals (including MyMedi.ca)

170+
Commercial listings (medical and adult-use)

10
Manufacturing Partners (Asset light model)

*As of January 2026



Established through the acquisition of



"We are grateful for the trust placed in us by our medical cannabis patients over the past few years, and are confident we've found the right partner in Avicanna to continue to support them. As we move away from medical cannabis distribution, we remain firm in our belief that this medication should be dispensed in pharmacies like all others and will continue our advocacy to that end."

- Jeff Leger, President, Shoppers Drug Mart

1.2 MyMedi.ca

A Complete Medical Cannabis
Care Platform



MyMedi.ca

MEDICAL CANNABIS CARE



1.2.1 MyMedi.ca Overview

Canada's Leading Medical Cannabis Care Platform

MyMedi.ca is a complete medical cannabis care platform for Canadian patients and the medical community.

MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients' needs and enhance the patient journey. MyMedi.ca is operated by Northern Green Canada Inc. under an agreement and features diverse portfolio of products and a pharmacist led patient support programs. MyMedi.ca also provided specialty services to distinct patient groups such as veterans and collaborating with public and private providers for adjudication and reimbursement and educational resources to facilitate the incorporation of medical cannabis into health care regimens.



Evidence-Based Product Access

- 200+ curated medical cannabis products from 35+ Canadian brands



Personalized Patient Care

- Bilingual, pharmacist-led support and specialty care programs



Education & Research Driven

- Resources for patients and healthcare professionals & ongoing clinical collaborations with leading institutions



Affordable & Accessible Treatment

- Compassionate pricing and coverage through private & public insurance




1.2.2. MyMedi.ca – Addressing The Gaps In Medical Cannabis Care




Overview:

- The most comprehensive medical cannabis care platform in the industry.
- Poised for international expansion with all pillars:



MyMedi.ca
MEDICAL CANNABIS CARE



E-commerce and Portfolio

- Virtual pharmacy optimized for medical cannabis patient care
- Curated portfolio for distinct patient groups and insurance providers
- Ongoing CRM and marketing initiatives




Patient Support Programs

- Clinical consults and treatment planning
- Insurance Adjudication
- Patient Education



Medical Affairs Programs

- Medical community education and training
- Medical community engagement and collaborations.
- Curated and distinct medical cannabis programs for medical institutions



Clinical Development & Insights

- Clinical development platform
- Data and insights including patient intelligence platform
- Ongoing RWE trials with leading KOLs and institutions



1.2.3 MyMedi.ca – Specialized Insurance Programs

Streamlined Insurance Program

- 14+ Partners across Canada
- Assist over 2500 patients annually to access their medical cannabis through their insurance provider
- Working together to create standardized formularies across Canada

Preferred Vendor Status

- Johnston Group
- Work Safety and Insurance Board (WSIB)
- Work Safe BC (WSBC)

Direct Manual Billing


- Worker Safety Boards
- Children's Aid Societies
- Community Services



Our focus on clinical excellence and insurance integration has earned the trust of national insurers. As a result, MyMedi.ca is now a preferred provider for several partners, making access to medical cannabis simpler and more consistent for patients.

1.2.4 Medical Affairs & Education Platform

Facilitating The Incorporation Of Medical Cannabis Into Standard Of Care



MyMedi.ca
MEDICAL CANNABIS CARE



AVICENNA
ACADEMY

- Practical guide on how to prescribe medical cannabis
- Guest Speakers & Webinars
- Symposium Recording Repository
- Indication Specific case studies
- Latest in Research Breakdowns



Educational Webinars For The Medical Community

| Modules | Topic & Guest Speakers |
|---|--|
| Medical Cannabis Research & Innovations | <p>Potential Role of Cannabigerol – Dr. Carrie Cutler (PhD, Executive Associate Professor, Director, Co-Director, Center for Cannabis Policy, Research, & Outreach (CCPRO), Department of Psychology Washington State University)</p> <p>Cannabinoids in Management of Arthritis – Dr. Jason McDougall (PhD, Depts. Pharmacology and Anesthesia, Dalhousie University)</p> |
| Challenges Faced by Patients & Breaking Barriers for Access | <p>Unique use cases of Medical Cannabis – Dr. Carlo De Angelis (PharmD, Clinician Scientist - Oncology Pharmacy, Department of Pharmacy Sunnybrook Odette Cancer Centre, University of Toronto)</p> <p>Building Better Educational Paradigms – Dr. Daniel Bear (PhD, Medical cannabis Director, Humber Centre for Social Innovation, Humber Polytechnic)</p> |
| Pain & Harm Reduction | <p>Substitution & Harm Reduction in High-Risk Populations – Dr. Zach Walsh (PhD, Psych, Professor, Psychology The University of British Columbia, Affiliated Scientist, BC Centre on Substance Use)</p> <p>Opioid-cannabinoid Interactions & Role of Opioids – Dr. Kelly Dunn (PhD, MBA, Director, Kahlert Institute for Addiction Medicine, Professor of Psychiatry and Neurobiology, University of Maryland)</p> |
| Medical Cannabis in Clinical Care | <p>Cannabis Use among Older Adults – Dr. Baumbusch (RN, PhD, FCAN, FAAN Professor UBC School of Nursing)</p> <p>Cannabinoids in Psychiatry – Dr. Katzman (BSc, MD, FRCPC, S.T.A.R.T. Clinic for the Mood and Anxiety Disorders, Northern Ontario School of Medicine & Psychology, Lakehead University)</p> <p>Cannabis in Epilepsy – Dr. Lewis (MD, FRCPC, North Toronto Neurology, University Of Toronto, Pediatrics)</p> |



1.3 Pharmaceutical Pipeline of Indication Specific Products

Developed through the Company's R&D, clinical
and commercial platforms



Medical Cannabis
Products



MyMedi.ca
MEDICAL CANNABIS CARE

Medical Cannabis
Care Platform*



Pharmaceutical
Pipeline

*MyMedi.ca is operated by Northern Green Canada for the Canadian market



1.3.1 Pharmaceutical Pipeline and Drug Candidates

Designed to Address 5 Major Clinical Areas



Sleep



Eczema/
Epidermolysis Bullosa



Pain
Management



Anxiety &
Depression



Epilepsy

- Candidates are in various stages of R&D, pre-clinical to real world evidence studies and or registration stage.
- Leveraging the company's scientific platform and vertical integration to deliver proprietary and accessible finished products.

| Drug Candidate | Delivery | Target | Status | Next Steps |
|---------------------------|----------|--|---|---|
| Trunerox™ | Oral | (LGS) and (DS) Childhood Catastrophic Epileptic Syndromes | Approved INVIMA, Colombia | Claim Expansion and Registration in LATAM |
| AVCN319301a & AVCN319301b | Oral | Pain associated with Osteoarthritis | GMP Pilot Completed | Phase II Initiated with UHN |
| AVCN583601 | Topical | Wound Healing, Pain and Itch associated with Epidermolysis Bullosa | Observational Clinical Trials Completed | Phase II Planning Stage |
| AVCN467504 | Topical | MSK Pain and Inflammation | Observational Clinical Trials Completed | Phase II Planning Stage |





1.3.2 Trunerox™ 10% CBD Oral Solution

Adjunctive Treatment of Seizures Associated with Lennox Gastaut Syndrome (LGS) and Dravet Syndrome (DS)

- Marketing authorization obtained in Colombia by INVIMA in 2024
- Domestic commercialization in Colombia in late 2025
- Proprietary formulation manufactured under GMP standards and utilizing the company's purified API

Prevalence Data

- Around 50 million people worldwide have epilepsy, one of the most common neurological diseases globally¹
 - High income countries: 49 per 100,000
 - Low-income and middle-income countries: 139 per 100,000
- Despite the availability of 28 FDA approved antiepileptic drugs nearly 40% of individuals lack seizure control²
- Prevalence to the action indication is nearly 10% of all pediatric epilepsy cases

1. Burden of epilepsy in Latin America and The Caribbean: a trend analysis of the Global Burden of Disease Study 1990 – 2019 Kevin Pacheco-Barrios,a,b,c,y* Alba Navarro-Flores,d,y Alejandra Cardenas-Rojas,b,y Paulo S. de Melo,b Elif Uygur-Kucukseymen,b,h Carlos Alva-Diaz, M.D.,e,i Felipe Fregni,b,f and Jorge G. Burneog

2. World Health Organization. (2024, February 7). Epilepsy Fact Sheet. <https://www.who.int/news-room/fact-sheets/detail/epilepsy>



invimö
Instituto Nacional de Vigilancia de Medicamentos y Alimentos

Sanitary registration
No. INVIMA 2024M-0021290



1.3.3 Osteoarthritic Pain Phase II Pilot (Initiated)

A UHN led internal Pilot, Placebo Controlled, Blinded Randomized Multicentre Trial

- The RCT is led Hance Clarke, MD, FRCPC, PhD as the principal investigator is the medical director of the Pain Research Unit, and a clinician at University Health Network and President of the Canadian pain Society
- The multi-site study commenced late 2025



Study Details

- Feasibility of a blinded, randomized, placebo-controlled, 3-arm, parallel group trial of oral cannabinoids for improving pain interference in patients with hip and/or knee osteoarthritis
- Funded by a Canadian Institutes of Health Research (“CHIR”) grant
- Sponsored by Avicanna that is providing its proprietary CBD and THC capsules produced under Good Manufacturing Practices (“GMP”) for the trial.



THE CANADIAN
PAIN SOCIETY

LA SOCIÉTÉ
CANADIENNE
DE LA DOULEUR



1.4 Active Pharmaceutical Ingredients (Aureus Santa Marta™)



1.4.1 Active Pharmaceutical Ingredients (Aureus Santa Marta™)

Avicanna's Supply Chain Business Segment and Vertical Integration

Supply Chain Business Pillar



- Avicanna's economical and **environmentally friendly** source of cannabinoids
- 3 international pharmaceutical marketing authorizations with Aureus API including Trunerox™
- Completed exports of cannabinoid API, flower and seed internationally including 20+ international markets



Established, Sustainable and Economical Cultivation and Extraction Infrastructure



- Majority owned subsidiary in Santa Marta Colombia with **300,000 square feet** and **26,000 kg of annual capacity**
- **USDA National Organic Program certified** and GACP certification
- Cultivating commercial crops of **CBD, CBG, THC and feminized seeds** since 2020



1.5 Avicanna Around the World

Global Operations and Exports - 22+ Countries

Commercial and Regulatory Expertise

Commercial activity in all 6 continents
Completed commercial sales/exports to 22 international markets:

Australia, Austria, Argentina, Barbados, Brazil, Canada, Colombia, Chile, Czech Republic, Ecuador, Denmark, Germany, Switzerland, South Singapore, Africa, Paraguay, Peru, Uruguay, UK, USA



CANADA

- MyMedi.ca Medical cannabis platform
- R&D and clinical platform
- Commercial platform 50+ commercial SKUs

COLOMBIA

- Aureus (SMGH) API and supply chain
- Commercial platform





2.0 Scientific Platform

R&D Platform Delivering Advanced and
Evidence-Based Cannabinoid Products



2.1 Established Scientific Platform



50+ Proprietary
Commercial Products



10+ Scientists



Extensive Pharmaceutical
Pipeline



IP Portfolio including
USPTO granted patents



11 Canadian Government Research
Grants Awarded Since 2020



100% Ownership of
All IP and Trade Secrets

2.2 World-Class Institutional Collaborations

20+ R&D, Pre-Clinical Studies and Collaborations with Canada's Leading Institutions Since 2017



THE CANADIAN
PAIN SOCIETY
LA SOCIÉTÉ
CANADIENNE
DE LA DOULEUR

3.0 Corporate Overview



AVICANNA™



3.1 Financial Highlights

9 Month 2025 Figures



\$18.8M revenue



EBITDA (\$0.5) - Near break-even



Gross Profits of 53% - Industry leading



Eliminated debt on the balance sheet

Other Figures



TSX: AVCN Senior Exchange - as a pharmaceutical issuer



Tightly Held – By management, board and strategic shareholders



3.2 Management and Board of Directors

Senior Management Team

Aras Azadian
Founder and CEO

Nick Hilborn
Interim Chief Financial Officer

Stephen Kim
Chief Legal Officer & General Counsel

Ivana Marić
Executive Vice President, Marketing

Dr. Karolina Urban, PhD
Executive Vice President, Medical &
Scientific Affairs

Board of Directors

Aras Azadian
Founder and CEO

Eileen McCormack
Independent Director


John McVicar
Independent Director

Giancarlo Davila Char
Director

Michael Kott
Director



3.3 Timeline and Evolution



3.4 Corporate Highlights

- **Scale-up and internalization stage** with 4 business pillars
- **Diversified** - scalable and high margin revenue streams focused on intellectual property
- **Addressing a global market opportunity** with medical and pharmaceutical cannabinoid-based products
- **50+ commercial SKUs** and first approved indication specific pharmaceutical
- **Vertical integration** - low-cost, organic and sustainable supply chain
- **Established scientific and medical leader** in cannabinoid-based medicine
- **Established intellectual portfolio** and pharmaceutical pipeline



AVICANNA™



MyMedi.ca
MEDICAL CANNABIS CARE



AUREUS
SANTA MARTA





AVICANNA™


Appendix



The Cannabinoid-Based Medicine Opportunity



The current challenge



The opportunity


10% of Canadian aged **16+** consumed cannabis for medical purposes: Only **18%** did so with a document from a healthcare professional

A **comprehensive medical cannabis solution** through the combination of Rho Phyto advanced products and the MyMedi.ca platform can capture a substantially larger market opportunity

MyMedi.ca MEDICAL CANNABIS CARE

International expansion built on Canadian proof of Concept

Medical cannabis use in Canada (symptoms, disease or disorder)






Addressing a multi billion-dollar marketing opportunity including:

- Sleep, Arthritis, Chronic Pain, Anxiety, and other Clinical Indications

The Separation of Adult-Use & Cannabinoid-Based Medicine



AVICANNA™

| |  Adult Use & Recreational |  Medical Cannabis |  CB Pharmaceuticals |
|-------------------------------------|--|--|--|
| End User | Consumers | Patients | Patients |
| Market Opportunity | Local State / Country | International | International |
| Product Forms | Mainly Inhalation, Edible | Basic to Advanced Formulations | Advanced (Non-inhalation) |
| Route to Market (Regulatory) | Fast (1-3 months) | Fast (3-24 months) | Slow (5-10 years) |
| IP Protection | Limited (Trademarks) | Mid-High (Trademark & Patent) | High (Patents) |
| Margins / Entry Barriers | Low-Mid (10-40%) | Mid-High (40-70%) | High (70%+) |
| Key Stakeholders / Channels | Dispensaries / Budtenders | HCPs / Medical Institutions / Payers | HCPs / Pharmacies / Payers |
| Competition | High | Low | Very Low |
| HCP Authorization | No | Yes | Yes - Product Specific |
| Insurance Coverage | No | Very Limited | Yes |
| Use | Recreational / Wellness | Wellness / Symptom Management | Indication Specific |
| Manufacturing / QA | GPP | GPP / GMP | GMP |
| | | RHO Phyto / MyMedi.ca | Trunerox / Pipeline |





AVICANNA™

Thank You

TSX: AVCN
avicanna.com
info@avicanna.com